查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594085

转移性乳癌治疗市场：按治疗类型、最终用户划分 - 全球预测 2025-2030

Metastatic Breast Cancer Treatment Market by Treatment Type (Biologic Targeted Therapy, Breast Surgery, Chemotherapy), End User (Clinics, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

转移性乳癌治疗市场2023年估值为216.6亿美元，预计到2024年将达到242.9亿美元，复合年增长率为12.20%，预计到2030年将达到485.3亿美元。

转移性乳癌治疗涉及一种综合方法，针对已从乳房扩散到身体其他部位的癌症。由于转移性癌症的复杂性及其对标准治疗方法的抵抗力，该领域最需要有效的治疗。这些治疗方法包括化疗、荷尔蒙疗法、标靶治疗和免疫治疗，主要最终用户是医院、癌症治疗中心和研究机构。市场成长主要是由个人化医疗的进步、乳癌盛行率的增加以及研发方面的大量投资所推动的。精准医学的出现代表了一个重大的成长机会，它根据基因理解来客製化治疗方法。製药公司和研究机构之间的合作也正在推动创新治疗方法和突破。然而，该市场面临治疗成本高、现有治疗方法相关的副作用、监管挑战以及新兴地区的经济负担问题等限制。新药严格的核准程序也增加了复杂性并减缓了市场成长。为了缓解这些挑战并利用目前的商机，技术创新的最佳领域包括开发毒性较小的疗法、增强药物输送系统以及探索联合治疗以提高疗效。对生物标记和基因组研究的关注将提供对患者特异性治疗的更深入的了解，并提高治疗结果的效率。另一方面，增加对生技新兴企业的创业投资可以加速创新。市场动态是动态的，高度依赖技术进步和科学研究。相关人员应监控正在进行的临床试验并形成策略联盟，以利用尖端解决方案实现永续成长。这些领域的策略考量指南公司在竞争格局中预测挑战并最大限度地发挥市场潜力。

主要市场统计
基准年[2023] 216.6亿美元
预测年份 [2024] 242.9亿美元
预测年份 [2030] 485.3亿美元
复合年增长率（%） 12.20%

市场动态：快速发展的转移性乳癌治疗市场的关键市场洞察

供应和需求的动态交互作用正在改变转移性乳癌治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 乳癌患者增加
    • 提高大众对转移性乳癌治疗的认识
    • 对电离辐射和紫外线辐射的开放性
  • 市场限制因素
    • 转移性乳癌的治疗费用昂贵
  • 市场机会
    • 癌症治疗领域的坚实技术进步
    • 转移性乳癌治疗的持续研究和开发
  • 市场挑战
    • 与治疗相关的副作用

波特五力：开拓转移性乳癌治疗市场的策略工具

波特的五力框架是了解转移性乳癌治疗市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解转移性乳癌治疗市场的外部影响

外部宏观环境因素在塑造转移性乳癌治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解转移性乳癌治疗市场的竞争格局

转移性乳癌治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵转移性乳癌治疗市场供应商的绩效评估

FPNV定位矩阵是评估转移性乳癌治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘转移性乳癌治疗市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对转移性乳癌治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 乳癌患者增加
      • 提高大众对转移性乳癌治疗的认识
      • 对电离辐射和紫外线辐射的开放性
    • 抑制因素
      • 转移性乳癌的治疗费用
    • 机会
      • 癌症治疗领域的强大技术进步
      • 转移性乳癌治疗的持续研究和开发
    • 任务
      • 与治疗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的转移性乳癌治疗市场

  • 生物标的治疗
  • 乳房手术
  • 化疗
  • 荷尔蒙疗法
  • 放射治疗

第七章转移性乳癌治疗市场：依最终用户分类

  • 诊所
  • 医院

第八章美洲转移性乳癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区转移性乳癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲转移性乳癌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-0363DFE03696

The Metastatic Breast Cancer Treatment Market was valued at USD 21.66 billion in 2023, expected to reach USD 24.29 billion in 2024, and is projected to grow at a CAGR of 12.20%, to USD 48.53 billion by 2030.

Metastatic breast cancer treatment involves a comprehensive approach targeting cancer that has spread beyond the breast to other parts of the body. The necessity for effective treatments in this area is paramount due to the complex nature of metastatic cancer and its resistance to standard therapies. Applications of these treatments range from chemotherapy, hormone therapy, targeted therapy, and immunotherapy, with the primary end-users being hospitals, cancer treatment centers, and research institutes. Market growth is significantly influenced by advancements in personalized medicine, increasing prevalence of breast cancer, and substantial investments in R&D. The emergence of precision medicine, which tailors treatment based on genetic understanding, presents a significant opportunity for growth. Collaborations between pharmaceutical companies and research institutions are also fostering innovative therapies and breakthroughs. However, the market faces limitations such as high treatment costs, side effects associated with existing therapies, regulatory challenges, and affordability issues in developing regions. The rigorous approval processes for new drugs add another layer of complexity, slowing the market growth. To mitigate these challenges and capitalize on the current opportunities, the best areas for innovation include the development of less-toxic therapeutic agents, enhancement of drug delivery systems, and the exploration of combination therapies that improve efficacy. A focus on biomarkers and genomic studies can provide deeper insights into patient-specific treatments, raising the efficiency of therapeutic outcomes. Meanwhile, an increasing amount of venture capital in biotech startups could accelerate innovation. The nature of the metastatic breast cancer treatment market is dynamic and heavily reliant on technological advancements and scientific research. Stakeholders should monitor ongoing clinical trials and engage in strategic alliances to leverage cutting-edge solutions for sustainable growth. Strategic insights into these areas can guide companies to both anticipate challenges and maximize their market potential in a competitive landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 21.66 billion
Estimated Year [2024] USD 24.29 billion
Forecast Year [2030] USD 48.53 billion
CAGR (%) 12.20%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Metastatic Breast Cancer Treatment Market

The Metastatic Breast Cancer Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing cases of breast cancers
    • Rise in awareness among people for metastatic breast cancer treatment
    • Openness to ionizing and ultraviolet radiation
  • Market Restraints
    • Costly procedures of metastatic breast cancer treatments
  • Market Opportunities
    • Robust technological advancement in the cancer treatments
    • Ongoing research and development in the metastatic breast cancer treatment
  • Market Challenges
    • Side effect associated with the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Metastatic Breast Cancer Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Metastatic Breast Cancer Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Metastatic Breast Cancer Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Metastatic Breast Cancer Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Metastatic Breast Cancer Treatment Market

A detailed market share analysis in the Metastatic Breast Cancer Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Metastatic Breast Cancer Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Metastatic Breast Cancer Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Metastatic Breast Cancer Treatment Market

A strategic analysis of the Metastatic Breast Cancer Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Metastatic Breast Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Bayer AG, Biocon Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Metastatic Breast Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Biologic Targeted Therapy, Breast Surgery, Chemotherapy, Hormone Therapy, and Radiation Therapy.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing cases of breast cancers
      • 5.1.1.2. Rise in awareness among people for metastatic breast cancer treatment
      • 5.1.1.3. Openness to ionizing and ultraviolet radiation
    • 5.1.2. Restraints
      • 5.1.2.1. Costly procedures of metastatic breast cancer treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust technological advancement in the cancer treatments
      • 5.1.3.2. Ongoing research and development in the metastatic breast cancer treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Side effect associated with the treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Metastatic Breast Cancer Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Biologic Targeted Therapy
  • 6.3. Breast Surgery
  • 6.4. Chemotherapy
  • 6.5. Hormone Therapy
  • 6.6. Radiation Therapy

7. Metastatic Breast Cancer Treatment Market, by End User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals

8. Americas Metastatic Breast Cancer Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Metastatic Breast Cancer Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Metastatic Breast Cancer Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Biocon Limited
  • 5. Eisai Co., Ltd.
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Gilead Sciences, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. METASTATIC BREAST CANCER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. METASTATIC BREAST CANCER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. METASTATIC BREAST CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. METASTATIC BREAST CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. METASTATIC BREAST CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METASTATIC BREAST CANCER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY BIOLOGIC TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY BREAST SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM METASTATIC BREAST CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. METASTATIC BREAST CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. METASTATIC BREAST CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023